-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Blueprint Medicines, Lowers Price Target to $130

Benzinga·04/28/2025 17:44:43
Listen to the news
Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and lowers the price target from $133 to $130.